Aklief is a groundbreaking, fourth-generation topical retinoid specifically engineered for the treatment of acne vulgaris.1 It is the first retinoid to selectively target Retinoic Acid Receptor (RAR)-2$\gamma$, the most prevalent RAR subtype in the skin.3 This precision targeting allows for high efficacy in reducing inflammatory and non-inflammatory lesions on the face, chest, shoulders, and back while minimizing the systemic irritation often associated with older retinoid generations.

Key Features

• Selective RAR-$\gamma$ Agonist: Targets the specific receptors responsible for skin cell turnover and inflammation, providing a more refined therapeutic effect.4
• Trunkal Acne Efficacy: Clinically proven and FDA-approved for use on large surface areas, including the back (bacne), chest, and shoulders.5
• Advanced Comedolytic Action: Accelerates follicular desquamation to clear existing comedones and prevent the formation of new microcomedones.
• Anti-Inflammatory Properties: Rapidly modulates the skin’s immune response to reduce the redness and swelling of papules and pustules.6
• Optimized Tolerability: Designed with a sophisticated cream vehicle that balances potency with skin barrier protection to reduce dryness and peeling.

Recommended Usage

• Application: Apply a thin layer to the affected areas once daily, preferably in the evening, after cleansing and drying the skin thoroughly.7
• Dosage: One pump actuation should cover the face; two pumps are typically sufficient for the upper trunk (chest and back).8
• Sun Sensitivity: Use a broad-spectrum SPF 30+ sunscreen daily, as retinoids increase dermal sensitivity to UV radiation.
• Patient Tip: To mitigate initial dryness (retinization), apply a non-comedogenic moisturizer immediately after the cream has absorbed.